[HTML][HTML] Liquid biopsy in pancreatic cancer: Are we ready to apply it in the clinical practice?
V Heredia-Soto, N Rodríguez-Salas, J Feliu - Cancers, 2021 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is one of the tumors with the
highest mortality, for which survival has hardly changed in the last 40 years. This high …
highest mortality, for which survival has hardly changed in the last 40 years. This high …
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
V Heredia-Soto, N Rodríguez-Salas, J Feliu - Cancers, 2021 - europepmc.org
Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
V Heredia-Soto, N Rodríguez-Salas, J Feliu - Cancers, 2021 - cir.nii.ac.jp
抄録< jats: p> Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of
all solid tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is …
all solid tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is …
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
V Heredia-Soto, N Rodríguez-Salas, J Feliu - Cancers, 2021 - pubmed.ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …
Liquid biopsy in pancreatic cancer: Are we ready to apply it in the clinical practice?
V Heredia-Soto, N Rodríguez-Salas, J Feliu - 2021 - lareferencia.info
Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …
Liquid biopsy in pancreatic cancer: Are we ready to apply it in the clinical practice?
V Heredia-Soto, N Rodríguez Salas, J Feliú Batlle - Cancers, 2021 - repositorio.uam.es
Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
V Heredia-Soto, N Rodríguez-Salas, J Feliu… - …, 2021 - search.ebscohost.com
Abstract Simple Summary: Pancreatic ductal adenocarcinoma (PDAC) is one of the tumors
with the highest mortality, for which survival has hardly changed in the last 40 years. This …
with the highest mortality, for which survival has hardly changed in the last 40 years. This …
[PDF][PDF] Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice? Cancers 2021, 13, 1986
V Heredia-Soto, N Rodríguez-Salas, J Feliu - 2021 - pdfs.semanticscholar.org
Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …
[HTML][HTML] Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
V Heredia-Soto, N Rodríguez-Salas, J Feliu - Cancers, 2021 - ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
V Heredia-Soto, N Rodríguez-Salas, J Feliu - Cancers, 2021 - search.proquest.com
Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to …